ASH 2024 | Update on the ASCEND-CML study investigating frontline asciminib for patients with CML
In this video, Timothy Hughes, MD, MBBS, FRACP, FRCPA, from South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, provides a brief update on the Australasian Leukaemia and Lymphoma Group (ALLG) CML13 ASCEND-CML study, a trial assessing asciminib monotherapy for newly diagnosed chronic myeloid leukemia (CML). The agent has led to deep and durable remissions and is well-tolerated, with only 6% of patients discontinuing therapy due to adverse events. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
In Australia we’re running the ASCEND study which is using asciminib monotherapy for patients with newly diagnosed chronic myeloid leukemia. We enrolled a hundred patients and we’ve been very impressed with the outcome so far. We’re now reporting results that are well out beyond two years and we’re achieving rates of major molecular response of over 80 percent...
In Australia we’re running the ASCEND study which is using asciminib monotherapy for patients with newly diagnosed chronic myeloid leukemia. We enrolled a hundred patients and we’ve been very impressed with the outcome so far. We’re now reporting results that are well out beyond two years and we’re achieving rates of major molecular response of over 80 percent. But more importantly we’re achieving very high rates of deep molecular response, and that’s giving us the potential to look at the option of treatment-free remission, which we’re planning to incorporate into the trial after four years. The tolerance to therapy has been very, very good. Only 6% of patients have come off because of adverse events. So we’re very pleased with the potential to use asciminib as a frontline therapy. I note that it’s just been approved by the FDA in the U.S. for frontline therapy and beyond.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Ariad: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Honoraria, Research Funding.
